Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice

0396260 - ÚOCHB 2014 RIV CZ eng J - Článek v odborném periodiku
Holubová, Martina - Špolcová, Andrea - Demianova, Zuzana - Sýkora, D. - Fehrentz, J. A. - Martinez, J. - Štofková, A. - Jurčovičová, J. - Drápalová, J. - Lacinová, Z. - Haluzík, M. - Železná, Blanka - Maletínská, Lenka
Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice.
Physiological Research. Roč. 62, č. 4 (2013), s. 435-444. ISSN 0862-8408. E-ISSN 1802-9973
Grant CEP: GA ČR GA303/09/0744; GA ČR GAP303/10/1368
Institucionální podpora: RVO:61388963
Klíčová slova: GHS-R agonists * JMV 1843 * male C57BL/6 mice * food intake * NPY/AgRP
Kód oboru RIV: CE - Biochemie
Impakt faktor: 1.487, rok: 2013

Ghrelin and agonists of its receptor GHS-R1a are potential substances for the treatment of cachexia. In the present study, we investigated the acute and long-term effects of the GHS-R1a agonist JMV 1843 (H-Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. Additionally, we examined stability of JMV 1843 in mouse blood serum. A single subcutaneous injection of JMV 1843 (0.01-10 mg/kg) increased food intake in fed mice in a dose-dependent manner, up to 5-times relative to the saline-treated group (ED50=1.94 mg/kg at 250 min). JMV 1843 was stable in mouse serum in vitro for 24 h, but was mostly eliminated from mouse blood after 2 h in vivo. Ten days of treatment with JMV 1843 (subcutaneous administration, 10 or 20 mg/kg/day) significantly increased food intake, body weight and mRNA expression of the orexigenic neuropeptide Y and agouti-related peptide in the medial basal hypothalamus and decreased the expression of uncoupling protein 1 in brown adipose tissue. Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia.
Trvalý link: http://hdl.handle.net/11104/0224137